Dr. Trefond et al reply: Giant Cell Arteritis After SARS-CoV-2 Vaccination—Coincidence or Trigger ?

References

1. 1.↵
   1. Conway R,
   2. Brouwer E,
   3. Geest KSM van der, et al

   . Dr. Conway et al reply. J Rheumatol 2021 Oct 1 (Epub ahead of print).
2. 2.↵
   1. Sauret A,
   2. Stievenart J,
   3. Smets P, et al

   . Case of giant cell arteritis after SARS-CoV-2 vaccination: a particular phenotype? J Rheumatol 2021 Oct 1 (Epub ahead of print).
3. 3.↵
   1. Machado PM,
   2. Lawson-Tovey S,
   3. Hyrich K, et al

   . Covid-19 vaccine safety in patients with rheumatic and musculoskeletal disease. Ann Rheum Dis 2021;80:199-200.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   1. Villa M,
   2. Díaz-Crespo F,
   3. Pérez de José A, et al

   . A case of ANCA-associated vasculitis after AZD1222 (Oxford-AstraZeneca) SARS-CoV-2 vaccination: casualty or causality? Kidney Int 2021;100:937-8.

   OpenUrl
5. 5.↵
   1. Parikh M,
   2. Miller NR,
   3. Lee AG, et al

   . Prevalence of a normal C-reactive protein with an elevated erythrocyte sedimentation rate in biopsy-proven giant cell arteritis. Ophthalmology 2006; 113:1842-5.

   OpenUrlCrossRefPubMed